Assessing consistent treatment effect in a multi-regional clinical trial: A systematic review

Pharmaceutical Statistics

Volumn 9, Issue 3, 2010, Pages 242-253

  Chen, Joshua ^a   Quan, Hui ^b   Binkowitz, Bruce ^a   Ouyang, S Peter ^c   Tanaka, Yoko ^d   Li, Gang ^e   Menjoge, Shailendra ^f   Ibia, Ekopimo ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b SANOFI   (France)

^c CELGENE CORPORATION   (United States)

^d ELI LILLY AND COMPANY   (United States)

^e JOHNSON AND JOHNSON   (United States)

^f BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

Consistency; Heterogeneity; Multi regional clinical trial; Qualitative; Quantitative

Indexed keywords

CLINICAL TRIAL; DRUG INDUSTRY; MULTIVARIATE ANALYSIS; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REVIEW; UNITED STATES;

CONTROLLED CLINICAL TRIALS AS TOPIC; DATA COLLECTION; GEOGRAPHY; GUIDELINES AS TOPIC; HUMANS; INTERNATIONALITY; META-ANALYSIS AS TOPIC; MULTICENTER STUDIES AS TOPIC; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 77957343984     PISSN: 15391604     EISSN: 15391612     Source Type: Journal    
DOI: 10.1002/pst.438     Document Type: Review

References (31)

1. O'Neill RT. Multi-regional clinical trials: a regulatory perspective on issues. Presented at the FDA/Industry Statistics Workshop, Washington, DC, September 24, 2009.
2. European Medicines Agency. Reflection paper on the extrapolation of results from clinical studies conducted outside Europe to the EU-population. EMEA Doc. Ref. CHMP/EWP/692702/2008. February 2009. Available at http://www.emea.europa.eu/pdfs/human/ewp/69270208en.pdf.
3. Ministry of Health, Labour and Welfare of Japan, Basic Principles on Global Clinical Trials. September 28, 2007.
4. Vickers A, Goyal N, Harland R, Rees R. Do certain countries produce only positive results? A systematic review of controlled trials. Controlled Clinical Trials 1998; 19:159-166.
5. ICH International Conference on Harmonization Tripartite Guidance E5: Ethnic Factor in the Acceptability of Foreign Data. The US Federal Register 1998; 83:31790-31796.
6. The Hirulog and Early Reperfusion or Occlusion (HERO)-2 Trial Investigators. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. Lancet 2001; 358:1855-1863.
7. Blair JEA, Zannad F, Konstam MA et al., for the EVEREST Investigators. Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure. Journal of the American College of Cardiology 2008; 52:1640-1648.
8. Akkerhuis KM, Deckers JW, Boersma E et al. for the PURSUIT Investigators. Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes. European Heart Journal 2000; 21:371-381.
9. Wedel H, DeMets D, Deedwania P et al. Challenges of subgroup analyses in multinational clinical trials: experiences from the MERIT-HF trial. American Heart Journal 2001; 142:502-511.
10. Kawai N et al. An approach to rationalize partitioning sample size into individual regions in a multiregional trial. Drug Information Journal 2008; 42:139-147.
11. Quan H, Zhao PL, Zhang J et al. Sample size considerations for Japanese patients in a multi-regional trial based on MHLW guidance. Pharmaceutical Statistics, DOI: 10.1002/pst.380.
12. Uesaka H. Sample size allocation to regions in a multiregional trial. Journal of Biopharmaceutical Statistics 2009; 19:580-594.
13. Hjalmarson A, Goldstein S, Fagerberg B et al. Effects of controlled release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). JAMA 2000; 283:1295-1302.
14. Cochran WG. The combination of estimates from different experiments. Biometrics 1954; 10:101-129.
15. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986; 7:177-188.
16. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. British Medical Journal 2003; 327:557-560.
17. Whitehead A. Meta-analysis of controlled clinical trials. Wiley: New York, 2002.
18. Fleiss. Analysis of data from multiclinic trials. Controlled Clinical Trials 1986; 7:267-275.
19. O'Shea JC, DeMets DL. Statistical issues relating to international differences in clinical trials. American Heart Journal 2001; 142:21-28.
20. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. New England Journal of Medicine 1998; 339: 436-443.
21. Gail M, Simon R. Testing for qualitative interaction between treatment effects and patient subsets. Biometrics 1985; 41:361-372.
22. Piantadosi S, Gail M. A comparison of the power of two tests for qualitative interactions. Statistics in Medicine 1993; 12:1239-1248.
23. Ciminera JL, Heyse JF, Nguyen HH, Tukey JW. Tests for qualitative treatment-by-centre interaction using a 'Pushback' procedure. Statistics in Medicine 1993; 12:1033-1045.
24. Chen YHJ, Liu GHF. Testing for crossover of two hazard functions using Gail and Simon's method. Journal of Biopharmaceutical Statistics 2006; 16: 313-326.
25. Chow SC, Shao J, Hu YP. Assessing sensitivity and similarity in bridging studies. Journal of Biopharmaceutical Statistics 2002; 12:385-400.
26. Lachenbruch PA, Rida W, Kou J. Lot consistency as an equivalence problem. Journal of Biopharmaceutical Statistics 2004; 14:275-290.
27. Quan H, Li M, Chen J et al. for the Consistency Workstream of the PhRMA MRCT Key Issue Team. Assessment of consistency of treatment effects in multi-regional clinical trials. Sanofi-Aventis Technical Report 034, September 2009.
28. Liu JP, Hsueh H, Chen J. Sample size requirements for evaluation of bridging evidence. Biometrical Journal 2002; 44:969-981.
29. FDA Medical Review of COZAARTM Tablets (Losartan Potassium). NDA 20-386/SE1-028, March 2002. Available at http://www.fda.gov/ohrms/dockets/ac/02/ briefing/3849b1-03-medicalreview.pdf.
30. Breslow NE, Day NE. Statistical methods in cancer research, volume 1: the analysis of case-control studies. International Agency for Research on Cancer: Lyon, 1980.
31. Pocock SJ, Assmann SE, Enos LE, Kasten LE. Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practice and problems. Statistics in Medicine 2002; 21:2917-2930.